Rekombinanter Thymidine Phosphorylase Antikörper (full length)
Kurzübersicht für Rekombinanter Thymidine Phosphorylase Antikörper (full length) (ABIN7879146)
Target
Alle Thymidine Phosphorylase (TYMP) Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- full length
-
Verwendungszweck
- Recombinant Thymidine Phosphorylase Antibody / PD-ECGF
-
Aufreinigung
- Protein A affinity chromatography
-
Immunogen
- Human recombinant full length protein was used as the immunogen for this recombinant Thymidine Phosphorylase antibody.
-
Isotyp
- IgG, kappa
-
-
-
-
Applikationshinweise
- The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the recombinant Thymidine Phosphorylase antibody to be titered up or down for optimal performance.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store the recombinant Thymidine Phosphorylase antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- Thymidine Phosphorylase (TYMP)
-
Andere Bezeichnung
- Thymidine Phosphorylase
-
Hintergrund
- Recognizes a 485 amino acid protein (55 kDa monomer / 110 kDa homodimer), identified as platelet-derived endothelial growth factor (PD-ECGF), also called Thymidine Phosphorylase (TP, Tymp) or Gliostatin. In the presence of inorganic orthophosphate, it catalyzes the reversible phospholytic cleavage of thymidine and deoxyuridine to their corresponding bases and 2-deoxyribose-1-phosphate. It is both chemotactic and mitogenic for endothelial cells and a non-heparin binding angiogenic factor present in platelets. Its enzymatic activity is crucial for angiogenic activity (metabolite is angiogenic). Higher levels of serum TP/PD-ECGF are observed in cancer patients. It is also involved in transformation of fluoropyrimidines, cytotoxic agents used in the treatment of a variety of malignancies, into active cytotoxic metabolites (e.g. 5 -deoxy-5-fluorouridine to 5-FU). High intra-cellular levels of TP/PD-ECGF are associated with increased chemosensitivity to such antimetabolites.
-
UniProt
- P19971
-
Pathways
- Signaling Events mediated by VEGFR1 and VEGFR2
Target
-